Wells Fargo & Company Navidea Biopharmaceuticals, Inc. Transaction History

Wells Fargo & Company

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.07 - $0.12 $9 - $16	140 Added 2.55%	5,632 $0
Q2 2023 Aug 15, 2023	BUY	$0.08 - $0.29 $1 - $6	21 Added 0.38%	5,492 $0
Q1 2023 May 12, 2023	SELL	$0.24 - $0.34 $438 - $621	-1,829 Reduced 25.05%	5,471 $1,000
Q4 2022 Feb 13, 2023	BUY	$0.18 - $0.3 $422 - $703	2,345 Added 47.33%	7,300 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.24 - $0.71 $0 - $0	1 Added 0.02%	4,955 $1,000
Q2 2022 Aug 12, 2022	SELL	$0.63 - $1.1 $8 - $14	-13 Reduced 0.26%	4,954 $3,000
Q1 2022 May 16, 2022	SELL	$0.72 - $1.2 $13 - $22	-19 Reduced 0.38%	4,967 $4,000
Q3 2021 Nov 15, 2021	BUY	$1.53 - $1.85 $18 - $22	12 Added 0.24%	4,986 $8,000
Q2 2021 Aug 16, 2021	BUY	$1.55 - $2.15 $4 - $6	3 Added 0.06%	4,974 $9,000
Q1 2021 May 13, 2021	BUY	$1.99 - $2.9 $59 - $87	30 Added 0.61%	4,971 $10,000
Q4 2020 Feb 09, 2021	SELL	$1.88 - $2.84 $1,541 - $2,328	-820 Reduced 14.23%	4,941 $10,000
Q3 2020 Nov 05, 2020	BUY	$2.69 - $4.95 $2,377 - $4,375	884 Added 18.13%	5,761 $15,000
Q2 2020 Aug 13, 2020	SELL	$0.7 - $4.16 $2,137 - $12,700	-3,053 Reduced 38.5%	4,877 $20,000
Q1 2020 May 14, 2020	BUY	$0.76 - $1.54 $6,026 - $12,212	7,930 New	7,930 $6,000

10.4K

Ticker NAVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,150,900
Description
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expr...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.